Research programme: cancer therapeutics - Ferrer/Vivia Biotech

Drug Profile

Research programme: cancer therapeutics - Ferrer/Vivia Biotech

Alternative Names: Cancer therapy - Ferrer/Vivia Biotech; FIB 114; Onco-therapy - Ferrer/Vivia Biotech

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ferrer; Vivia Biotech
  • Developer Ferrer
  • Class Cell therapies; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Spain (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Spain (Parenteral)
  • 11 Dec 2012 Ferrer and Vivia Biotech agree to co-develop FIB 114 in Spain for Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top